F2-Isoprostanes

• 

  Subject Areas on Research

  • 8-ISO-PGF2alpha production by alveolar macrophages exposed to hyperoxia. 
  • African Ancestry Gradient Is Associated with Lower Systemic F2-Isoprostane Levels. 
  • Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. 
  • Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study. 
  • Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. 
  • F2-isoprostanes: a measure of oxidative stress in children receiving treatment for leukemia. 
  • Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. 
  • NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. 
  • Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. 
  • Racial differences in urinary F2-isoprostane levels and the cross-sectional association with BMI. 
  • Role of nonenzymatically generated prostanoid, 8-iso-PGF2 alpha, in pulmonary oxygen toxicity. 
  • Systemic markers of oxidative status and colorectal adenomatous polyps. 
  • Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome. 
  • Thromboxane receptor signalling in renal ischemia reperfusion injury. 
  • Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. 
  • Urinary F2-isoprostanes and metabolic markers of fat oxidation. 
  • Urinary F2-isoprostanes and the risk of hypertension. 
  • Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. 
  • Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes. 
  • Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort. 
  • Urinary biomarkers of oxidative status in a clinical model of oxidative assault. 
  • Urinary biomarkers of oxidative status.